InfinixBio

InfinixBio is a full-service, Columbus, Ohio-based Contract Research Organization (CRO) founded in 2006. The company provides interdisciplinary scientific support for the biotech, pharmaceutical, and medical device industries, operating in GLP-compliant and BSL-2 laboratories. Their service offerings include early-stage drug development, assay development and validation, protein biochemistry, genetic engineering, and bio-production optimization. The company utilizes a proprietary process known as the Rapid Innovate Model™ to streamline project management and accelerate client technologies from proof of concept through preclinical testing and early-stage clinical trial development toward regulatory approval. Their team, which includes a high percentage of PhD scientists, has collectively secured over 50 patents and maintains a collaborative business model that does not require equity or IP ownership from clients.

For partners and customers, InfinixBio functions as an outsourced research and development arm, helping organizations overcome complex scientific and regulatory hurdles. They specialize in tailoring solutions for challenges such as manufacturing yield optimization, animal model selection, and the creation of diagnostic assays for 510(k) and LDT submissions. By assigning dedicated project management teams, they offer a single point of contact designed to minimize risk and improve communication efficiency. Their work has been instrumental in assisting clients with IND submissions, enabling clinical trial advancement, and securing significant funding, demonstrating a track record of translating complex laboratory research into viable regulatory and clinical outcomes.